Hanall Biopharma Co., Ltd.

Immunomet Therapeutics Inc.

Korea Research Institute of Chemical Technology

Korea Research Institute of Bioscience and Biotechnology

Hanall Pharmaceutical Company, Ltd.

Sung Wuk Kim

Sung Soo Jun

Ji Sun Lee

Jae Kap Jeong

Yeon Jung Song

Eun Sun Kim

Seung Kook Park

Duck Kim

Yong Eun Kim

Chang Hee Min

Ju Hoon Oh

Se Hwan Park

Hong Bum Lee

Young Woong Kim

Hye Jin Heo

Hong Woo Kim

Young Gwan Jo

Ja Seong Koo

Ji Ae Kook

Hyea Kyung Ahn

Min Sun Kim

Hae-Young Yong

Dongok Shin

Min Woo Kang

Ha Na Kim

Sang Dal Rhee

Won Hoon Jung

Hyae Gyeong Cheon

Byung Kyu Oh

Song Young Kim

Sang Hee Yoo

Tae Hyoung Yoo

Jong Cheol Lee

Young Woo Lee

Jae Woon Son

Soon Im Lee

Kwang Rok Kim

Jae Seung Lee

Hee Young Kim

Jae Ho Cheong

Kyung-Sook Chung

Yong Mann Song

Min Jeong Kim

Woong Cho

Jong-Cheol Lee

Kwang-Rok Kim

Dae Heok Kwon

Seok Gu Kang

Jong Y Jeon

Jong Hee Chang

Myung Jin Son

Kang M Lee

Eun Kyoung Shin

Jiae Kook

Sanghee Yoo

Jiwon Ahn

Youjeong Kwon

Jeong Haing Heo

Min Jae Shin

Mi Jeong Kim

Kook Hwan Oh

Kyung Don Ju

Seonju Mun

Hye Soun Eum

Hung Keun Lee

Jun Jeong Choi

Byoung Ha Kim

Ji Hyun Lee

Jae Sung Ryu

Ja-Seong Koo

Jin Wook Kim

The present invention relates to a composition for hair improvement, and more specifically to a composition for promoting hair growth, or preventing or treating hair loss, comprising a guanine derivative having no toxicity as an active ingredient. The composition has excellent effects of promoting hair growth and regenerating hair follicles, and thus can be effectively used in various fields such as pharmaceutical, food, feed, and cosmetic compositions for promoting hair growth, or preventing, treating, and improving hair loss.

Composition for promoting hair growth comprising a guanine derivative

The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Antibody binding to FCRN for treating autoimmune diseases

The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

Biguanide compound and use thereof

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

Guanidine compounds and use thereof

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

Antibody binding to FcRn for treating autoimmune diseases

A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK&#x3b1; and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

FcRn-specific human antibody and composition for treatment of autoimmune diseases

The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT.

Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis

A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK&#x3b1; and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNF&#x3b1; neutralizing activity, and inhibits TNF&#x3b1; activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.

Uses of modified human tumor necrosis factor receptor-1 polypeptide

An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same

The present invention provides novel uses of a biguanide derivative for preventing or treating glioblastoma. The compound of Formula 1 and its pharmaceutically acceptable salts can be used for preventing and treating glioblastoma. Further, the combined treatment of the compound of Formula 1 and temozolomide can provide superior effects compared to the administration of the compound of Formula 1 alone or temozolomide alone.

Pharmaceutical composition comprising a biguanide derivative as an active ingredient for preventing or treating glioblastoma

Growing community of inventors

Gyeonggi-do, South Korea

Sung Wuk Kim